Showing results (11-20 of 41) with videos related to
Sort By:
Pageof 5
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|July 23, 2005
Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzoleC Paillisse, L Lacomblez, M Dib, et al.Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|June 14, 2002
Long-term safety of riluzole in amyotrophic lateral sclerosisL Lacomblez, G Bensimon, P N Leigh, et al.European Journal of Clinical Pharmacology|January 1, 1987
Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluationD Warot, L Bergougnan, D Lamiable, et al.Journal of the Neurological Sciences|February 8, 2019
Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysisEdward Fox, Maria Cecilia Vieira, Kristen Johnson, et al.Therapie|July 2, 2002
[Tolerance of riluzole in a phase IIIb clinical trial]L Lacomblez, M Dib, V Doppler, et al.Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|September 14, 2011
Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysisDavid G Binion, Edouard Louis, Bas Oldenburg, et al.Current Medical Research and Opinion|July 16, 2010
Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensivesWeiyi Yang, Joanne Chang, Kristijan H Kahler, et al.Current Medical Research and Opinion|November 8, 2019
Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims studyMaria Cecilia Vieira, Devon Conway, Gina Mavrikis Cox, et al.Neurology|December 1, 1996
A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-IIL Lacomblez, G Bensimon, P N Leigh, et al.Clinical Genitourinary Cancer|May 3, 2023
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United StatesYizhen Lai, Arielle G Bensimon, Emily Gao, et al.Pageof 5